BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018;5:ofy120. [PMID: 29992173 DOI: 10.1093/ofid/ofy120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Klinker H, Naumann U, Rössle M, Berg T, Bondin M, Lohmann K, Koenig B, Zeuzem S, Cornberg M. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver Int 2021;41:1518-22. [PMID: 33966349 DOI: 10.1111/liv.14937] [Reference Citation Analysis]
2 Lazarus JV, Øvrehus A, Demant J, Krohn-Dehli L, Weis N. The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). BMJ Open 2020;10:e039724. [PMID: 33168560 DOI: 10.1136/bmjopen-2020-039724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hershow RB, Gonzalez M, Costenbader E, Zule W, Golin C, Brinkley-Rubinstein L. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. AIDS Educ Prev 2019;31:363-79. [PMID: 31361517 DOI: 10.1521/aeap.2019.31.4.363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int 2020;40:51-9. [PMID: 31509639 DOI: 10.1111/liv.14247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Molinari M, Kaltenmeier C, Samra P, Liu H, Wessel C, Lou Klem M, Dharmayan S, Emmanuel B, Al Harakeh H, Tohme S, Geller D, Tevar A, Hughes CB, Humar A, Bataller R, Behari J. Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients. Annals of Surgery Open 2021;2:e065. [DOI: 10.1097/as9.0000000000000065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Koustenis KR, Anagnostou O, Kranidioti H, Vasileiadi S, Antonakaki P, Koutli E, Pantsas P, Deutsch M, Manolakopoulos S. Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting. Ann Gastroenterol. 2020;33:195-201. [PMID: 32127741 DOI: 10.20524/aog.2020.0449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, Wong J, Rossi C, Butt ZA, Bartlett S, Pearce ME, Samji H, Cook D, Alvarez M, Chong M, Tyndall M, Krajden M, Janjua NZ. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat 2020;27:243-60. [PMID: 31664755 DOI: 10.1111/jvh.13228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
8 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2021:S0210-5705(21)00251-X. [PMID: 34543719 DOI: 10.1016/j.gastrohep.2021.09.003] [Reference Citation Analysis]
9 Byrne C, Robinson E, Rae N, Dillon JF. Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real-world outcomes. Health Sci Rep. 2020;3:e191. [PMID: 33033752 DOI: 10.1002/hsr2.191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, Alvarez J, Pulido L, Cañamares I, Escobar I, Moreno S, Ryan P. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. [PMID: 31253391 DOI: 10.1016/j.drugpo.2019.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Abdelwadoud M, Mattingly TJ 2nd, Seguí HA, Gorman EF, Perfetto EM. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. Patient 2021;14:471-84. [PMID: 33372245 DOI: 10.1007/s40271-020-00489-6] [Reference Citation Analysis]
12 Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N, Klein MB; Canadian Coinfection Cohort Study Investigators. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? Clin Infect Dis 2021;73:468-77. [PMID: 32504083 DOI: 10.1093/cid/ciaa702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. Int J Drug Policy 2021;:103238. [PMID: 33902968 DOI: 10.1016/j.drugpo.2021.103238] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis 2021;53:612-9. [PMID: 32917546 DOI: 10.1016/j.dld.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group. Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. Int J Drug Policy 2021;96:103422. [PMID: 34426040 DOI: 10.1016/j.drugpo.2021.103422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Foschi FG, Borghi A, Grassi A, Lanzi A, Speranza E, Vignoli T, Napoli L, Olivoni D, Sanza M, Polidori E, Greco G, Bassi P, Cristini F, Ballardini G, Altini M, Conti F, On Behalf Of Mith Group. Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. J Clin Med 2021;10:4001. [PMID: 34501448 DOI: 10.3390/jcm10174001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study. Hepatol Commun 2021. [PMID: 34729957 DOI: 10.1002/hep4.1826] [Reference Citation Analysis]
18 Benitez TM, Fernando SM, Amini C, Saab S. Geographically Focused Collocated Hepatitis C Screening and Treatment in Los Angeles's Skid Row. Dig Dis Sci 2020;65:3023-31. [PMID: 31974916 DOI: 10.1007/s10620-020-06073-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis 2021;8:ofaa564. [PMID: 33447634 DOI: 10.1093/ofid/ofaa564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:754-767. [PMID: 30245064 DOI: 10.1016/s2468-1253(18)30304-2] [Cited by in Crossref: 103] [Cited by in F6Publishing: 39] [Article Influence: 25.8] [Reference Citation Analysis]
21 Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, Gentile I, Sogari F, Pierri P, Surace LA, Morisco F, Tundo P, Brancaccio G, Serviddio G, Gatti P, Termite AP, Di Costanzo GG, Caroleo B, Cozzolongo R, Coppola N, Longo A, Fontanella L, Federico A, Rosato V, Terrenato I, Masarone M. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver Int. 2019;39:1852-1859. [PMID: 31175707 DOI: 10.1111/liv.14170] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
22 Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, Holmes JA, Yu R, Zhu C, Yang S, Lin W, Chung RT. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver Int 2021. [PMID: 34051040 DOI: 10.1111/liv.14976] [Reference Citation Analysis]
23 Goodyear T, Ti L, Carrieri P, Small W, Knight R. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy 2020;81:102766. [PMID: 32416525 DOI: 10.1016/j.drugpo.2020.102766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
24 Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. International Journal of Drug Policy 2022;102:103588. [DOI: 10.1016/j.drugpo.2022.103588] [Reference Citation Analysis]
25 Ridziauskas M, Zablockienė B, Jančorienė L, Samuilis A, Zablockis R, Jackevičiūtė A. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. Medicina (Kaunas) 2021;57:210. [PMID: 33652777 DOI: 10.3390/medicina57030210] [Reference Citation Analysis]
26 Conway B, Smyth D, Thomas R, Wong A, Sebastiani G, Cooper C, Shah H, Kumar R, Deutsch G, Watson T. Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT). CanLivJ 2021;4:346-59. [DOI: 10.3138/canlivj-2021-0005] [Reference Citation Analysis]